XBiotech (XBIT) News Today → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free XBIT Stock Alerts $7.25 -0.24 (-3.20%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Stock Crosses Below Fifty Day Moving Average of $8.40May 25, 2024 | finance.yahoo.comXBiotech Inc. (XBIT)May 24, 2024 | seekingalpha.comXBiotech: Several Shots On Goal In Big Target Market IndicationsMay 13, 2024 | investorplace.comXBIT Stock Earnings: XBiotech Reported Results for Q1 2024April 25, 2024 | finance.yahoo.comXBiotech Inc. (XBIT) Stock Price, News, Quote & History - Yahoo FinanceApril 24, 2024 | money.usnews.comXBiotech IncMarch 20, 2024 | finance.yahoo.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insidersMarch 18, 2024 | investorplace.comXBIT Stock Earnings: XBiotech Reported Results for Q4 2023March 14, 2024 | marketbeat.comXBiotech Inc. (NASDAQ:XBIT) Short Interest Up 35.4% in FebruaryXBiotech Inc. (NASDAQ:XBIT - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 29th, there was short interest totalling 537,500 shares, an increase of 35.4% from the February 14th total of 397,000 shares. Currently, 2.7% of the company's shares are sold short. Based on an average daily trading volume, of 36,700 shares, the short-interest ratio is presently 14.6 days.March 8, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Quince Therapeutics and XBiotechFebruary 17, 2024 | finance.yahoo.comXBIT Mar 2024 5.000 callFebruary 15, 2024 | marketbeat.comXBiotech (NASDAQ:XBIT) Shares Cross Above 50 Day Moving Average of $4.56XBiotech (NASDAQ:XBIT) Shares Pass Above 50-Day Moving Average of $4.56February 15, 2024 | marketbeat.comXBiotech Inc. (NASDAQ:XBIT) Short Interest UpdateXBiotech Inc. (NASDAQ:XBIT - Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 376,500 shares, a growth of 9.6% from the January 15th total of 343,500 shares. Based on an average trading volume of 24,300 shares, the days-to-cover ratio is presently 15.5 days. Currently, 1.9% of the company's shares are sold short.February 7, 2024 | marketbeat.comXBiotech (NASDAQ:XBIT) Stock Price Passes Above Fifty Day Moving Average of $4.37XBiotech (NASDAQ:XBIT) Shares Cross Above 50 Day Moving Average of $4.37February 7, 2024 | marketbeat.comXBiotech (NASDAQ:XBIT) Research Coverage Started at StockNews.comStockNews.com initiated coverage on XBiotech in a report on Wednesday. They issued a "sell" rating on the stock.January 18, 2024 | morningstar.comXBiotech Inc XBITJanuary 8, 2024 | bizjournals.comA top Austin biopharmaceutical company is doubling down on its Austin campusJanuary 4, 2024 | finance.yahoo.comXBiotech to Begin Constructing New R&D Facility on its 48-acre CampusDecember 15, 2023 | msn.comARCT, EHTH and CRTO are among after hour moversDecember 5, 2023 | finance.yahoo.comCompanies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In GrowthNovember 14, 2023 | finanznachrichten.deXBiotech Inc.: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid ArthritisNovember 14, 2023 | finance.yahoo.comDr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisSeptember 28, 2023 | marketbeat.comXBiotech Inc. (NASDAQ:XBIT) Short Interest Up 72.4% in SeptemberXBiotech Inc. (NASDAQ:XBIT - Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 254,400 shares, an increase of 72.4% from the August 31st total of 147,600 shares. Approximately 1.4% of the shares of the company are sold short. Based on an average daily volume of 21,400 shares, the short-interest ratio is presently 11.9 days.September 26, 2023 | finance.yahoo.comXBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeAugust 8, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialAugust 8, 2023 | finance.yahoo.comXBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialJune 30, 2023 | thestreet.comXBiotech Cancer Drug Survival Claim Falls Apart Under ScrutinyJune 2, 2023 | marketbeat.comStockNews.com Initiates Coverage on XBiotech (NASDAQ:XBIT)StockNews.com began coverage on shares of XBiotech in a research report on Friday. They issued a "hold" rating for the company.May 23, 2023 | finanznachrichten.deXBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 22, 2023 | finance.yahoo.comFDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesMay 17, 2023 | finance.yahoo.comXBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesApril 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 17, 2023 | finance.yahoo.comXBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 9, 2023 | finance.yahoo.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insidersApril 4, 2023 | marketbeat.comXBiotech (NASDAQ:XBIT) Earns Hold Rating from Analysts at StockNews.comStockNews.com started coverage on XBiotech in a research note on Tuesday. They set a "hold" rating for the company.February 15, 2023 | finance.yahoo.comThe past three years for XBiotech (NASDAQ:XBIT) investors has not been profitableNovember 15, 2022 | marketbeat.comXBiotech (NASDAQ:XBIT) Cut to Sell at StockNews.comStockNews.com cut XBiotech from a "hold" rating to a "sell" rating in a report on Tuesday.November 12, 2022 | marketbeat.comShort Interest in XBiotech Inc. (NASDAQ:XBIT) Grows By 42.4%XBiotech Inc. (NASDAQ:XBIT - Get Rating) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 96,100 shares, a growth of 42.4% from the October 15th total of 67,500 shares. Based on an average daily volume of 42,800 shares, the short-interest ratio is currently 2.2 days. Approximately 0.6% of the shares of the company are sold short.November 11, 2022 | finance.yahoo.comXBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)October 31, 2022 | finance.yahoo.comInsiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the companyOctober 18, 2022 | prnewswire.comHelicobacter pylori Infection Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2022-2032) | DelveInsight - PR NewswireOctober 18, 2022 | marketbeat.comXBiotech (NASDAQ:XBIT) Lowered to "Sell" at StockNews.comStockNews.com lowered shares of XBiotech from a "hold" rating to a "sell" rating in a research report on Tuesday.October 13, 2022 | finance.yahoo.comXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - Yahoo FinanceOctober 13, 2022 | globenewswire.comXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - GlobeNewswireOctober 13, 2022 | finance.yahoo.comXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal CancerSeptember 29, 2022 | marketbeat.comXBiotech Inc. (NASDAQ:XBIT) Short Interest Down 22.2% in SeptemberXBiotech Inc. (NASDAQ:XBIT - Get Rating) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 69,000 shares, a decrease of 22.2% from the August 31st total of 88,700 shares. Based on an average daily trading volume, of 84,800 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.4% of the company's stock are short sold.September 8, 2022 | finance.yahoo.comXBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year agoSeptember 2, 2022 | marketbeat.comStockNews.com Lowers XBiotech (NASDAQ:XBIT) to SellStockNews.com downgraded shares of XBiotech from a "hold" rating to a "sell" rating in a research report on Friday.September 2, 2022 | nasdaq.comWe Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - Nasdaq Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now XBIT Media Mentions By Week XBIT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XBIT News Sentiment▼0.940.76▲Average Medical News Sentiment XBIT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XBIT Articles This Week▼20▲XBIT Articles Average Week Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OPK News Today LQDA News Today IRWD News Today OCUL News Today IMNM News Today SPRY News Today ABVX News Today GYRE News Today TYRA News Today IRON News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XBIT) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceLEAKED: Jeff Bezos' $330 Million GambleBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
